Search Results

Current strategies in the treatment of Parkinson's disease and a personalized approach to management

Authors: Diaz, Nancy L; Waters, Cheryl H

Source: Expert Review of Neurotherapeutics, Volume 9, Number 12, December 2009 , pp. 1781-1789(9)

Publisher: Expert Reviews

Established therapies and novel targets in the treatment of Parkinson's disease

Authors: Dézsi, Livia; Vécsei, László

Source: Expert Review of Clinical Pharmacology, Volume 2, Number 6, November 2009 , pp. 631-644(14)

Publisher: Expert Reviews

Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease

Authors: Naoi, Makoto; Maruyama, Wakako

Source: Expert Review of Neurotherapeutics, Volume 9, Number 8, August 2009 , pp. 1233-1250(18)

Publisher: Expert Reviews

Levodopa-related wearing-off in Parkinson's disease: identification and management

Authors: Pahwa, Rajesh; Lyons, Kelly E.

Source: Current Medical Research and Opinion, Volume 25, Number 4, April 2009 , pp. 841-849(9)

Publisher: Informa Healthcare

Selegiline transdermal system: a novel treatment option for major depressive disorder

Authors: Nandagopal, Jayasree J; DelBello, Melissa P

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 10, July 2009 , pp. 1665-1673(9)

Publisher: Informa Healthcare

Duloxetine: A Review of its Use in the Treatment of Generalized Anxiety Disorder

Authors: Carter, Natalie J.; McCormack, Paul L.

Source: CNS Drugs, Volume 23, Number 6, 30 May 2009 , pp. 523-541(19)

Publisher: Adis International

5-hydroxytryptamine induced relaxation in the pig urinary bladder neck

Authors: Recio, Paz; Barahona, María Victoria; Orensanz, Luis M; Bustamante, Salvador; Martínez, Ana Cristina; Benedito, Sara; García-Sacristán, Albino; Prieto, Dolores; Hernández, Medardo

Source: British Journal of Pharmacology, Volume 157, Number 2, May 2009 , pp. 271-280(10)

Publisher: Blackwell Publishing

Ecstasy-induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A

Authors: Alves, Ema; Summavielle, Teresa; Alves, Cecília Juliana; Custódio, José Barata Antunes; Fernandes, Eduarda; de Lourdes Bastos, Maria; Tavares, Maria Amélia; Carvalho, Félix

Source: Addiction Biology, Volume 14, Number 2, April 2009 , pp. 185-193(9)

Publisher: Blackwell Publishing

In a recent report, Decision Resources suggests that second-line patient share of monoamine oxidase B (MAO B) inhibitors has increased

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 574, 2009-03-21 , pp. 7-7(1)

Publisher: Adis International

Drugs Used to Treat Parkinson's Disease, Present Status and Future Directions

Author: Abdel-Salam, Omar M.E.

Source: CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets, Volume 7, Number 4, October 2008 , pp. 321-342(22)

Publisher: Bentham Science Publishers

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

Authors: Elmer, Lawrence W; Bertoni, John M

Source: Expert Opinion on Pharmacotherapy, Volume 9, Number 16, November 2008 , pp. 2759-2772(14)

Publisher: Informa Healthcare

Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson's Disease

Authors: Gallagher, David A.; Schrag, Anette

Source: CNS Drugs, Volume 22, Number 7, 2008 , pp. 563-586(24)

Publisher: Adis International

Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

Authors: Zhu, Wen; Xie, Wenjie; Pan, Tianhong; Jankovic, Joseph; Li, Jun; Youdim, Moussa B. H.; Le, Weidong

Source: Journal of Neurochemistry, Volume 105, Number 5, June 2008 , pp. 1970-1978(9)

Publisher: Blackwell Publishing

Therapeutic Strategies in Parkinson's Disease

Author: Bharath, Muchukunte M.S.

Source: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Volume 2, Number 2, June 2008 , pp. 135-147(13)

Publisher: Bentham Science Publishers

Progress in neuroprotection in Parkinson's disease

Author: Schapira, A. H. V.

Source: European Journal of Neurology, Volume 15, Supplement 1, April 2008 , pp. 5-13(9)

Publisher: Blackwell Publishing

Manage levodopa-induced motor complications in patients with Parkinson's disease with careful selection of other antiparkinsonian agents

Author: Adis International Limited,

Source: Drugs & Therapy Perspectives, Volume 24, Number 1, January 2008 , pp. 17-21(5)

Publisher: Adis International

Spotlight on Rasagiline in Parkinson's Disease

Authors: Oldfield, Vicki; Keating, Gillian M.; Perry, Caroline M.

Source: CNS Drugs, Volume 22, Number 1, 2008 , pp. 83-86(4)

Publisher: Adis International

The Evolution of Pharmacological Treatment for Parkinson's Disease

Authors: Almeida, Quincy J.; Hyson, H. C.

Source: Recent Patents on CNS Drug Discovery, Volume 3, Number 1, January 2008 , pp. 50-54(5)

Publisher: Bentham Science Publishers

New insights into the structures and functions of human monoamine oxidases A and B

Authors: Edmondson, D. E.; DeColibus, L.; Binda, C.; Li, M.; Mattevi, A.

Source: Journal of Neural Transmission, Volume 114, Number 6, June 2007 , pp. 703-705(3)

Publisher: Springer

Variations in activity and inhibition with pH: the protonated amine is the substrate for monoamine oxidase, but uncharged inhibitors bind better

Authors: Jones, T. Z. E.; Balsa, D.; Unzeta, M.; Ramsay, R. R.

Source: Journal of Neural Transmission, Volume 114, Number 6, June 2007 , pp. 707-712(6)

Publisher: Springer